Osteoporosis After Orchiectomy for Prostate Cancer (1997)

No AccessJournal of UrologyClinical Urology: Original Article1 Feb 1997Osteoporosis After Orchiectomy for Prostate Cancer Harry W. Daniell Harry W. DaniellHarry W. Daniell More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)65165-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The possibility of increased osteoporosis and osteoporotic fractures following therapeutic orchiectomy in men with prostate cancer was investigated. Materials and Methods: A total of 235 men with nonstage A prostate cancer diagnosed between 1983 and 1990 was analyzed for therapeutic orchiectomy, other osteoporotic risk factors and subsequent hospital treatment for osteoporotic fractures. The 17 castrated men alive in 1995 were interviewed, and femoral neck bone mineral density was compared to that of 23 controls of similar age. Results: Risk factors for osteoporosis, including smoking, slender habitus and atrophic testes, were common among men treated with orchiectomy. Of the men in the study cohort 10 had osteoporotic fractures: 8 of 59 treated with and 2 of 176 without orchiectomy (13.6 versus 1.1%, p <0.001). First fracture cumulative incidence rates 7 years after castration or diagnosis were 28 and 1%, respectively (p <0.001). Osteoporotic fractures were much more common than pathological fractures or those due to major trauma (1 each). Bone mineral density averaged 0.91, 0.84, 0.79 and 0.66 gm./cm.2 in 9 controls without prostate cancer, 14 men with prostate cancer before orchiectomy, 9 men at 9 to 60 and 8 men at 60 to 115 months after orchiectomy, respectively. Of the 16 men surviving for longer than 60 months after orchiectomy 6 had osteoporotic fractures, as did 5 of 6 and 5 of 7 with a bone mineral density of less than 0.70 gm./cm.2 and less than 75% of normal for age, respectively. Conclusions: Orchiectomy for prostate cancer is frequently followed by severe osteoporosis, some of which had developed before castration. Appropriate therapy should be identified that does not diminish the antitumorigenic effectiveness of androgen ablation. References 1 : Severe osteoporosis in men. Ann. Intern. Med.1995; 123: 452. Google Scholar 2 : Risk factors for spinal osteoporosis in men. Amer. J. Med.1983; 75: 977. Google Scholar 3 : Pathogenesis of vertebral crush fractures in men. Age Aging1992; 21: 139. Google Scholar 4 : Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men?. J. Amer. Geriatr. Soc.1991; 39: 766. Google Scholar 5 : Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Amer. J. Med. Sci.1992; 304: 4. Google Scholar 6 : Carcinoma of the prostate. In: Adult and Pediatric Urology. Edited by . St. Louis: The C. V. Mosby Co.1991: 1277. part 1, chapt. 34. Google Scholar 7 : Adenocarcinoma of the prostate. In: Campbell's Urology. Edited by . Philadelphia: W. B. Saunders Co.1992: 1159. chapt. 29. Google Scholar 8 : Prostate cancer. In: Cancer, Principals and Practices of Oncology. Edited by . Philadelphia: J. B. Lippincott Co.1993: 1073. Google Scholar 9 : Management of hormonal treatment effects. Cancer1995; 75: 1983. Google Scholar 10 : Hormonal therapy in the treatment of carcinoma of the prostate. Cancer1995; 75: 1914. Google Scholar 11 : A worse prognosis for smokers with prostate cancer. J. Urol.1995; 154: 153. Link, Google Scholar 12 : A better prognosis for obese men with prostate cancer. J. Urol.1996; 155: 220. Link, Google Scholar 13 Daniell, H. W. and Tam, E. W.: Increased testicular atrophy following prostate bed radiation therapy for prostate cancer. Unpublished data. Google Scholar 14 : Osteoporosis of the slender smoker. Vertical compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity. Arch. Intern. Med.1976; 136: 298. Google Scholar 15 : Prognostic factors of advanced prostatic carcinoma. Ann. Chir. Gynaec.1993; 206: 9. Google Scholar 16 : Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J. Urol.1989; 141: 1139. Link, Google Scholar 17 : Pre-treatment testosterone levels: significance in androgen deprivation therapy. J. Urol.1986; 136: 1038. Link, Google Scholar 18 : Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. J.A.M.A.1991; 265: 618. Google Scholar 19 : Analysis of prognostic factors in men with metastatic prostate cancer. J. Urol.1991; 146: 372. Abstract, Google Scholar 20 : Prognostic value of serum hormone concentrations in prostatic cancer. Prostate1988; 13: 249. Google Scholar 21 : Plasma testosterone levels in patients with prostatic carcinoma before and after treatment. J. Urol.1968; 99: 788. Link, Google Scholar 22 : Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J. Clin. Endocr. Metab.1989; 69: 523. Google Scholar 23 : Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann. Intern. Med.1987; 106: 354. Google Scholar 24 : Treatment of fibroids with the combination of the GnRH agonist goserelin (Zoladex) and hormone replacement therapy. Adv. Reprod. Endocr.1992; 4: 135. Google Scholar 25 : The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J. Clin. Endocr. Metab.1988; 67: 701. Google Scholar 26 : Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3. J. Clin. Endocr. Metab.1990; 70: 1055. Google Scholar 27 : Hypogonadism induced by leutinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women. Brit. Med. J.1987; 294: 1523. Google Scholar 28 : Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp sup 6-GnRH). J. Clin. Endocr. Metab.1993; 76: 288. Google Scholar 29 : Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J. Urol.1995; 154: 535. Link, Google Scholar 30 : Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif. Tissue Int.1994; 54: 327. Google Scholar 31 : LHRH agonists and vertebral osteoporosis in men: two cases. Ann. Med. Int.1995; 146: 284. Google Scholar 32 : Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur. J. Surg. Oncol.1987; 13: 41. Google Scholar 33 : Preferential preservation of bone mineralisation by LHRH agonists in the treatment of metastatic prostate cancer. Eur. Urol.1991; 19: 114. Google Scholar 34 : Flutamide-mediated androgen blockade evokes osteopenia in the female rat. J. Bone Miner. Res.1993; 8: 763. Google Scholar 35 : FSH and LH elevation after radiation for treatment of cancer of the prostate. Invest. Urol.1979; 16: 278. Google Scholar 36 : The effects of external beam radiotherapy on endocrine function in patients with carcinoma of the prostate. J. Urol.1986; 135: 726. Link, Google Scholar 37 : Effects of external radiation therapy for cancer of the prostate on the serum concentrations of testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin. J. Urol.1983; 130: 287. Link, Google Scholar 38 : The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer. Scand. J. Urol. Nephrol.1993; 27: 475. Google Scholar Department of Family Practice, University of California Medical School at Davis, Redding, California.© 1997 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByMistry R, Hughes D, Wadhwa V and Parr N (2018) Lateral Spine Radiographs Before Androgen Deprivation Treatment Detect a High Incidence of Undiagnosed Vertebral Fragility Fractures in Men With Advanced Prostate CancerJournal of Urology, VOL. 186, NO. 2, (474-481), Online publication date: 1-Aug-2011.Maroni P and Crawford E (2018) Assessment of Men Before Androgen Deprivation TherapyJournal of Urology, VOL. 186, NO. 2, (371-372), Online publication date: 1-Aug-2011.Alibhai S, Duong-Hua M, Cheung A, Sutradhar R, Warde P, Fleshner N and Paszat L (2018) Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 MenJournal of Urology, VOL. 184, NO. 3, (918-924), Online publication date: 1-Sep-2010.Koopmans N, de Jong I, Breeuwsma A and van der Veer E (2018) Serum Bone Turnover Markers (PINP and ICTP) for the Early Detection of Bone Metastases in Patients With Prostate Cancer: A Longitudinal ApproachJournal of Urology, VOL. 178, NO. 3, (849-853), Online publication date: 1-Sep-2007.Smith M, Boyce S, Moyneur E, Duh M, Raut M and Brandman J (2018) Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate CancerJournal of Urology, VOL. 175, NO. 1, (136-139), Online publication date: 1-Jan-2006.Morote J, Orsola A, Abascal J, Planas J, Trilla E, Raventos C, Cecchini L, Encabo G and Reventos J (2018) Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen SuppressionJournal of Urology, VOL. 175, NO. 5, (1679-1683), Online publication date: 1-May-2006.Srinivas S and Colocci N (2018) Bone Related Events in High Risk Prostate CancerJournal of Urology, VOL. 176, NO. 6S, (S50-S54), Online publication date: 1-Dec-2006.SIEBER P, KEILLER D, KAHNOSKI R, GALLO J and MCFADDEN S (2018) BICALUTAMIDE 150 MG MAINTAINS BONE MINERAL DENSITY DURING MONOTHERAPY FOR LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCERJournal of Urology, VOL. 171, NO. 6 Part 1, (2272-2276), Online publication date: 1-Jun-2004.DIAMOND T, BUCCI J, KERSLEY J, ASLAN P, LYNCH W and BRYANT C (2018) OSTEOPOROSIS AND SPINAL FRACTURES IN MEN WITH PROSTATE CANCER: RISK FACTORS AND EFFECTS OF ANDROGEN DEPRIVATION THERAPYJournal of Urology, VOL. 172, NO. 2, (529-532), Online publication date: 1-Aug-2004.SMITH M (2018) OSTEOPOROSIS AND OBESITY IN MEN RECEIVING HORMONE THERAPY FOR PROSTATE CANCERJournal of Urology, VOL. 172, NO. 5S, (S52-S57), Online publication date: 1-Nov-2004.DICKMAN P, ADOLFSSON J, ÅSTRÖM K and STEINECK G (2018) HIP FRACTURES IN MEN WITH PROSTATE CANCER TREATED WITH ORCHIECTOMYJournal of Urology, VOL. 172, NO. 6 Part 1, (2208-2212), Online publication date: 1-Dec-2004.MELTON L, ALOTHMAN K, KHOSLA S, ACHENBACH S, OBERG A and ZINCKE H (2018) Fracture Risk Following Bilateral OrchiectomyJournal of Urology, VOL. 169, NO. 5, (1747-1750), Online publication date: 1-May-2003.SCHERR D and PITTS W (2018) The Nonsteroidal Effects of Diethylstilbestrol: The Rationale for Androgen Deprivation Therapy Without Estrogen Deprivation in the Treatment of Prostate CancerJournal of Urology, VOL. 170, NO. 5, (1703-1708), Online publication date: 1-Nov-2003.HIGANO C (2018) Management of Bone Loss in Men With Prostate CancerJournal of Urology, VOL. 170, NO. 6S, (S59-S64), Online publication date: 1-Dec-2003.SCHERR D, PITTS W and VAUGHAN E (2018) DIETHYLSTILBESTEROL REVISITED: ANDROGEN DEPRIVATION, OSTEOPOROSIS AND PROSTATE CANCERJournal of Urology, VOL. 167, NO. 2 Part 1, (535-538), Online publication date: 1-Feb-2002.Oefelein M, Ricchiuti V, Conrad W and Resnick M (2018) Skeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate CancerJournal of Urology, VOL. 168, NO. 3, (1005-1007), Online publication date: 1-Sep-2002.Fowler J, Bigler S, White P and Duncan W (2018) Hormone Therapy for Locally Advanced Prostate CancerJournal of Urology, VOL. 168, NO. 2, (546-549), Online publication date: 1-Aug-2002.BERRUTI A, DOGLIOTTI L, TERRONE C, CERUTTI S, ISAIA G, TARABUZZI R, REIMONDO G, MARI M, ARDISSONE P, DE LUCA S, FASOLIS G, FONTANA D, ROCCA ROSSETTI S and ANGELI A (2018) Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation TherapyJournal of Urology, VOL. 167, NO. 6, (2361-2367), Online publication date: 1-Jun-2002.ROSS R and SMALL E (2018) Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate CancerJournal of Urology, VOL. 167, NO. 5, (1952-1956), Online publication date: 1-May-2002.Walsh P (2018) UROLOGIC ONCOLOGY: PROSTATE CANCERJournal of Urology, VOL. 167, NO. 1, (408-416), Online publication date: 1-Jan-2002.OEFELEIN M, RICCHUITI V, CONRAD W, SEFTEL A, BODNER D, GOLDMAN H and RESNICK M (2018) SKELETAL FRACTURE ASSOCIATED WITH ANDROGEN SUPPRESSION INDUCED OSTEOPOROSIS: THE CLINICAL INCIDENCE AND RISK FACTORS FOR PATIENTS WITH PROSTATE CANCERJournal of Urology, VOL. 166, NO. 5, (1724-1728), Online publication date: 1-Nov-2001.Walther M and Pitts W (2018) RE: MEDICAL VERSUS SURGICAL ANDROGEN SUPPRESSION THERAPY FOR PROSTATE CANCER: A 10-YEAR LONGITUDINAL COST STUDYJournal of Urology, VOL. 166, NO. 2, (632-632), Online publication date: 1-Aug-2001.STRAUB B, MÜLLER M, SCHRADER M, HEICAPPELL R and MILLER K (2018) OSTEOPOROSIS AND MILD METABOLIC ACIDOSIS IN THE RAT AFTER ORCHIECTOMY AND THEIR PREVENTION: SHOULD PROPHYLACTIC THERAPY BE ADMINISTERED TO PATIENTS WITH ANDROGEN DEPRIVATION?Journal of Urology, VOL. 165, NO. 5, (1783-1789), Online publication date: 1-May-2001.DANIELL H, DUNN S, FERGUSON D, LOMAS G, NIAZI Z and STRATTE P (2018) PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCERJournal of Urology, VOL. 163, NO. 1, (181-186), Online publication date: 1-Jan-2000.VAN VELDHUIZEN P, TAYLOR S, WILLIAMSON S and DREES B (2018) TREATMENT OF VITAMIN D DEFICIENCY IN PATIENTS WITH METASTATIC PROSTATE CANCER MAY IMPROVE BONE PAIN AND MUSCLE STRENGTHJournal of Urology, VOL. 163, NO. 1, (187-190), Online publication date: 1-Jan-2000. Volume 157Issue 2February 1997Page: 439-444 Advertisement Copyright & Permissions© 1997 by American Urological Association, Inc.MetricsAuthor Information Harry W. Daniell More articles by this author Expand All Advertisement PDF DownloadLoading ...